Levine M M, Galen J, Barry E, Noriega F, Chatfield S, Sztein M, Dougan G, Tacket C
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA.
J Biotechnol. 1996 Jan 26;44(1-3):193-6. doi: 10.1016/0168-1656(95)00094-1.
Attenuated Salmonella typhi vaccine strain CVD 908, which harbors deletion mutations in aroC and aroD, has been shown to be well-tolerated and highly immunogenic, eliciting impressive serum antibody, mucosal IgA and cell-mediated immune responses. A further derivative prepared by introducing a deletion in htrA (which encodes a heat-shock protein that also has activity as a serine protease in CVD 908 (Chatfield et al., unpublished data) resulted in CVD 908-htrA. In phase 1 clinical trials, CVD 908-htrA appears very attractive as a live oral vaccine candidate. Both CVD 908 and CVD 908-htrA are useful as live vector vaccines to deliver foreign antigens to the immune system. Conditions that enhance the expression and immunogenicity of foreign antigens carried by CVD 908 and CVD 908-htrA are being investigated.
伤寒沙门氏菌减毒疫苗株CVD 908，其aroC和aroD基因存在缺失突变，已被证明耐受性良好且免疫原性高，能引发令人印象深刻的血清抗体、黏膜IgA和细胞介导的免疫反应。通过在htrA（编码一种热休克蛋白，在CVD 908中也具有丝氨酸蛋白酶活性，Chatfield等人，未发表数据）中引入缺失而制备的进一步衍生物产生了CVD 908-htrA。在1期临床试验中，CVD 908-htrA作为一种口服活疫苗候选物显得非常有吸引力。CVD 908和CVD 908-htrA都可用作活载体疫苗，将外源抗原递送至免疫系统。目前正在研究增强CVD 908和CVD 908-htrA携带的外源抗原表达和免疫原性的条件。
